多重耐药铜绿假单胞菌感染治疗药物研究进展

Research advances of antibiotics on multidrug-resistant Pseudomonas aeruginosa infections

多重耐药铜绿假单胞菌(Pseudomonas aeruginosa,PA)是院内感染的常见病原体之一,可同时通过多种耐药机制对常见抗菌药物产生耐药性,显著增加感染治疗难度和患者死亡率,已成为全球公共卫生难题。本文综述了PA感染的流行病学、危险因素及对常用抗菌药物的耐药特性,分析多重耐药PA感染治疗药物头孢洛扎/他唑巴坦、头孢他啶/阿维巴坦、亚胺培南-西司他汀/雷巴坦及头孢地尔的敏感性判定标准及其临床应用,以期为临床应用提供参考。

Multidrug-resistant Pseudomonas aeruginosa has become one of the common pathogens of nosocomial infections.It can simultaneously develop resistance to common antibiotics through multiple resistance mechanisms.Increasing treatment difficul⁃ties and patient mortality significantly,it has become a global public health challenge.This review focused upon the epidemiologi⁃cal features and risk factors of Pseudomonas aeruginosa infection,the resistance characteristics to commonly used antibiotics and analyzes the sensitivity criteria and clinical applications of new antibiotics against multidrug-resistant Pseudomonas aeruginosa including ceftolozane/tazobactam,ceftazidime/avibactam,imipenem-cilastatin/relebactam and cefiderocol.It may provide refer⁃ences for clinical applications.